Sign In
glob
Find HeartFlow

Unlocking the Power
of Coronary CTA

The modern way to diagnose coronary artery disease

The path to diagnosing coronary artery disease (CAD) hasn’t always been clear or reliable.1,2 Until now.

The CT-Flow™ pathway enables physicians to more accurately diagnose patients with suspected CAD by combining two powerful, non-invasive technologies — coronary CTA (CCTA) and the HeartFlow Analysis.1

WATCH THE VIDEO

How does the CT-Flow pathway work?

+

The CT-Flow pathway begins with a CCTA. If the physician sees disease, the CCTA images are sent to HeartFlow, where AI algorithms, computational fluid dynamics and trained analysts create the HeartFlow Analysis. This personalized, color-coded 3-D model of a patient’s coronary arteries provides functional information about each blockage.

How is the CT-Flow pathway different?

To address the current gaps in cardiac diagnostic testing, the CT-Flow pathway:

  • Delivers better per-vessel diagnostic performance than other non-invasive cardiac tests1
  • Provides both anatomical and lesion-specific functional information in a single patient visit
  • Identifies functional disease other non-invasive cardiac tests may overlook1,2
  • Limits invasive testing by allowing physicians to identify patients who can be treated with optimal medical therapy alone3
  • Reduces radiation exposure by up to 50% (compared to a SPECT test)4
  • Leads to better clinical decision-making and improved patient outcomes5
Download Brochure
Contact Us

How do non-invasive CAD tests compare?

CT-Flow Pathway
SPECT Stress Echo Coronary CTA HeartFlow Analysis
Common Questions
Does my patient have CAD?
X
X
X
X
Do the vessels have plaque?
X
X
Where are the coronary artery specific stenoses?
X
X
Is there possible ischemia?
X
X
X
What are the lesion-specific functional limitations?
X
Which vessels may benefit from PCI/CABG/OMT?
X
Is prognostic information provided?
X
X
X
X
Diagnostic Performance*
Sensitivity: 0.42
Specificity: 0.97
AUC: 0.792
Sensitivity: 0.77
Specificity: 0.75
AUC: 0.7010
Sensitivity: 0.68
Specificity: 0.83
AUC: 0.832
Sensitivity: 0.90
Specificity: 0.86
AUC: 0.942
Disadvantages2, 10-14
Low sensitivity; high rate of false negatives; higher radiation exposure; lacks anatomic data
Often requires additional testing; lacks anatomic data
High sensitivity can lead to overutilization of invasive testing when not paired with functional information
Requires CCTA; Currently not as well known as other tests
Advantages2, 10-14
Accessible; high specificity; standard of care
Accessible; no radiation
Better long-term outcomes than usual care testing; lower radiation; provides anatomic data
More accurate than other non-invasive tests; provides anatomic and functional information; lower radiation; single patient visit

* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischemia.

SPECT Stress Echo Coronary CTA HeartFlow Analysis
HeartFlow Analysis
Common Questions
Stress Echo
Common Questions
Coronary CTA
Common Questions
SPECT
Common Questions
Does my patient have CAD?
X
Do the vessels have plaque?
Where are the coronary artery specific stenoses?
Is there possible ischemia?
X
What are the lesion-specific functional limitations?
Which vessels may benefit from PCI/CABG/OMT?
Is prognostic information provided?
X
Does my patient have CAD?
X
Do the vessels have plaque?
Where are the coronary artery specific stenoses?
Is there possible ischemia?
X
What are the lesion-specific functional limitations?
Which vessels may benefit from PCI/CABG/OMT?
Is prognostic information provided?
X
Does my patient have CAD?
X
Do the vessels have plaque?
X
Where are the coronary artery specific stenoses?
X
Is there possible ischemia?
What are the lesion-specific functional limitations?
Which vessels may benefit from PCI/CABG/OMT?
Is prognostic information provided?
X
Does my patient have CAD?
X
Do the vessels have plaque?
X
Where are the coronary artery specific stenoses?
X
Is there possible ischemia?
X
What are the lesion-specific functional limitations?
X
Which vessels may benefit from PCI/CABG/OMT?
X
Is prognostic information provided?
X
Diagnostic Performance*
Sensitivity: 0.42
Specificity: 0.97
AUC: 0.792
Disadvantages2, 10-14
Low sensitivity; high rate of false negatives; higher radiation exposure; lacks anatomic data
Advantages2, 10-14
Accessible; high specificity; standard of care
Diagnostic Performance*
Sensitivity: 0.77
Specificity: 0.75
AUC: 0.7010
Disadvantages2, 10-14
Often requires additional testing; lacks anatomic data
Advantages2, 10-14
Accessible; no radiation
Diagnostic Performance*
Sensitivity: 0.68
Specificity: 0.83
AUC: 0.832
Disadvantages2, 10-14
High sensitivity can lead to overutilization of invasive testing when not paired with functional information
Advantages2, 10-14
Better long-term outcomes than usual care testing; lower radiation; provides anatomic data
Diagnostic Performance*
Sensitivity: 0.90
Specificity: 0.86
AUC: 0.942
Disadvantages2, 10-14
Requires CCTA; Currently not as well known as other tests
Advantages2, 10-14
More accurate than other non-invasive tests; provides anatomic and functional information; lower radiation; single patient visit

Click to expand

Click to collapse

Click to expand

* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischemia.

Click to collapse

How do patients benefit?

The CT-Flow pathway addresses the current gaps in traditional diagnostic testing – where patients may be misdiagnosed due to inaccurate test results.1,2

SEE PATIENT CASES
patient small.bcef5f5d

Frequently Asked Questions

The CT-Flow pathway provides the highest diagnostic performance available from a non-invasive test to help identify functional disease.1,2 This pathway leads to targeted treatment plans and a more streamlined patient experience.

Physicians can use the CT-Flow pathway for any clinically stable symptomatic patient with CAD. The pathway requires access to a standard CT scanner and an institution that offers the HeartFlow Analysis. Find a center near you using our finder tool or contact your local HeartFlow representative.

Within hours, physicians can receive the HeartFlow Analysis, which is available on desktop and mobile.

 

CT-Flow offers a streamlined workflow that reduces unnecessary invasive testing and radiation exposure, and provides more accurate information about their condition compared to other non-invasive cardiac tests.1,2,3,4 The highly visual, color-coded model resonates well with patients and can help increase adherence to treatment plans.

Both CCTA and the HeartFlow Analysis, the two steps of the CT-Flow pathway, are commercially available. The HeartFlow Analysis is FDA cleared and reimbursed by CMS and most major commercial insurers. It’s currently available at more than 400 institutions worldwide — in the United States, United Kingdom, Europe, Canada and Japan — and has been used for more than 100,000 patients to date.

Additional Resources

Contact Us

* Required fields

REFERENCES

  1. Driessen, et al. J Am Coll Cardiol 2019; Norgaard, et al, Euro J Radiol 2015.
  2. Melikian, et al. JACC: Cardiovasc Interv 2010; Jung, et al. Euro Heart J 2008. Koo, et al. J Am Coll; Cardiol 2011. Min, et al. JAMA 2012. Nørgaard, et al. J Am Coll Cardiol 2014.
  3. Patel, et al. J Am Coll Cardiol 2019.
  4. Stocker, et al. Euro Heart J 2018.
  5. Curzen, N.P., et al., J Am Coll Cardiol 2016. Newby D.E., et al. N Engl J Med 2018.
  6. Danad, et al., Euro Heart J 2017.
cert logo hitrust.7394f2b.cda83af2e008d8cc68f55103dbde7712

The information provided by the HeartFlow FFRCT Analysis, RoadMap Analysis, and Plaque Analysis from the HeartFlow ONE platform and the HeartFlow Planner is intended to be used in conjunction with the patient's clinical history, symptoms and other diagnostic tests, as well as the clinician's professional judgment. The HeartFlow FFRCT Analysis, RoadMap Analysis, Plaque Analysis and HeartFlow Planner may not be appropriate for all patients. See their respective indications for use for more information. The HeartFlow FFRCT Analysis has received FDA Clearance, is CE-Marked, and is commercially available in the United States, Europe, Japan and Canada. The RoadMap Analysis and Plaque Analysis have received FDA Clearance and are commercially available in the United States. The HeartFlow Planner has received FDA Clearance and is commercially available in the United States.

© 2023 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041

69473005 v2

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます！

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.

本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？

いいえ
はい